PR Newswire·Apr 30, 2026, 4:05 PM ET

Illumina Reports Financial Results for First Quarter of Fiscal Year 2026

Illumina reported Q1 2026 revenue of $1.09 billion, representing a 4.8% increase from Q1 2025 with 3.5% organic growth in the rest-of-world region.
The company recorded a GAAP operating margin of 19.2% and a non-GAAP operating margin of 21.9% for the quarter.
Diluted earnings per share (EPS) were $0.87 on a GAAP basis and $1.15 on a non-GAAP basis for Q1 2026.
On April 28, 2026, the Board of Directors authorized an additional $1.5 billion in share repurchases.
Illumina raised its fiscal year 2026 total revenue guidance to $4.52-$4.62 billion, increasing the mid-point by $20 million from prior expectations.
Full-year non-GAAP operating margin guidance was adjusted to 23.4%-23.6%, while non-GAAP diluted EPS guidance was raised to $5.15-$5.30.
Free cash flow for Q1 2026 totaled $251 million, derived from $289 million in operating cash flow minus $38 million in capital expenditures.
Demand for the NovaSeq X platform is increasing as clinical customers expand into new application areas, according to CEO Jacob Thaysen.
The company held $1.16 billion in cash, cash equivalents, and short-term investments at the close of the quarter.
Forward-looking statements in the release were accompanied by a detailed list of risks, including regulatory uncertainties in China, tariff impacts, integration of the SomaLogic acquisition, and pending litigation related to the GRAIL acquisition.